Who has been buying Pharma Research stock?

3 distinct insiders have filed 5 disclosed insider purchases in Pharma Research (214450), most recently on 2026-04-06. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Pharma Research have?

Pharma Research has 5 buy-side and 1 sell-side disclosures on record, covering ₩412M ($286K) in total reported value, spanning 2024-10-09 to 2026-04-06.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Pharma Research 214450

Company

파마리서치Pharma Research

Insiders

Buys

Total Value

₩412M ($286K)

Avg Return

-4.88%

Last Filing

2026-04-06

Pharma Research (214450) has 5 disclosed insider purchases and 1 disclosed disposals on record, filed by 3 distinct insiders. Together those filings cover ₩412M ($286K) in reported transaction value. The earliest filing StockDrifts holds for Pharma Research is dated 2024-10-09; the most recent is 2026-04-06. Across these filings the average return since disclosure is -4.88%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-04-06	BUY	Market Buy	김이환 Lee Hwan Kim	Head of Financial Management Division	350	₩285,500	+13.8%	₩100M ($69K)
2026-02-12	BUY	Market Buy	윤관식 Yoon Gwan-sik	Managing Director	5	₩348,500	+2.0%	₩2M ($1K)
2026-02-11	BUY	Market Buy	윤관식 Yoon Gwan-sik	Managing Director	75	₩343,500	+3.5%	₩26M ($18K)
2026-01-01	BUY	신규선임	유용선 Yongseon Yoo	Managing Director	132	₩434,000	-18.1%	₩57M ($40K)
2025-10-30	SELL	Market Sell	정래준 Raejun Jeong	Managing Director	-500	₩544,000	+34.6%	₩272M ($189K)
2025-09-22	BUY	Market Buy	정래준 Raejun Jeong	Managing Director	9	₩609,000	-41.6%	₩5M ($4K)
2025-09-22	BUY	Market Buy	정래준 Raejun Jeong	Managing Director	11	₩609,000	-41.6%	₩7M ($5K)
2025-03-25	BUY	신규선임	정래준 Raejun Jeong	Managing Director	1.8K	₩319,500	+11.3%	₩569M ($395K)
2025-03-25	BUY	신규선임	정래승 Jeong Rae-seung	Internal director	10.0K	₩319,500	+11.3%	₩3.2B ($2.2M)
2024-10-09	BUY	제3자배정유상증자	PolishCompanyLimited	major shareholders	1.2M	₩212,500	+67.3%	₩249.8B ($173.5M)

Frequently asked questions

Who has been buying Pharma Research stock?: 3 distinct insiders have filed 5 disclosed insider purchases in Pharma Research (214450), most recently on 2026-04-06. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Pharma Research have?: Pharma Research has 5 buy-side and 1 sell-side disclosures on record, covering ₩412M ($286K) in total reported value, spanning 2024-10-09 to 2026-04-06.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.